Biogen (BIIB) Property, Plant & Equipment (Net) Growth (1y) (2010 - 2026)
Biogen (BIIB) Property, Plant & Equipment (Net) Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.44% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 9.71% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.99% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 20.68% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 5.25% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 24.68% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 6.85% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.35% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.22% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -3.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.38% |
| Mar 31, 2026 | -3.66% |
| Dec 31, 2025 | -3.96% |
| Sep 30, 2025 | -4.21% |
| Jun 30, 2025 | -4.63% |
| Mar 31, 2025 | -4.36% |
| Dec 31, 2024 | -3.88% |
| Sep 30, 2024 | 3,954.17% |
| Jun 30, 2024 | -1.75% |
| Mar 31, 2024 | -0.78% |
| Dec 31, 2023 | 0.34% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | -1.43% |
| Mar 31, 2023 | -2.13% |
| Dec 31, 2022 | -3.45% |
| Sep 30, 2022 | -97.68% |
| Jun 30, 2022 | -2.53% |
| Mar 31, 2022 | -1.91% |
| Dec 31, 2021 | 0.14% |
| Sep 30, 2021 | 1.51% |